Methods and compositions for synthesis of two-photon cleavable phosphoramidite molecules for oligonucleotide conjugation
US-11938187-B2 · Mar 26, 2024 · US
Medicinal agent for medical applications
US9333266B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9333266-B2 |
| Application number | US-201214131613-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 9, 2012 |
| Priority date | Aug 11, 2011 |
| Publication date | May 10, 2016 |
| Grant date | May 10, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a medicinal agent for medical applications, which can act on the function of a target cell specifically. The medicinal agent for medical applications comprises: a cell-incorporated substance that can be incorporated into a target cell specifically; and an acting substance that can act on the function of the target cell and is bound to the cell-incorporated substance.
First claim
Opening claim text (preview).
The invention claimed is: 1. A medicinal agent for medical applications, comprising: serotonin conjugated with an anticancer substance for a rhabdomyosarcoma, wherein said anticancer substance is selected from the group consisting of paclitaxel, cisplatin, carboplatin, doxorubicin and cyclophosphamide. 2. The medicinal agent for medical applications according to claim 1 , wherein the anticancer substance is paclitaxel. 3. The medicinal agent for medical applications according to claim 1 , wherein the anticancer substance is cisplatin. 4. The medicinal agent for medical applications according to claim 1 , wherein the anticancer substance is carboplatin. 5. The medicinal agent for medical applications according to claim 1 , wherein the anticancer substance is doxorubicin. 6. The medicinal agent for medical applications according to claim 1 , wherein the anticancer substance is cyclophosphamide.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer · CPC title
for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title
Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title
- A61K47/54Primary
the modifying agent being an organic compound · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9333266B2 cover?
- Provided is a medicinal agent for medical applications, which can act on the function of a target cell specifically. The medicinal agent for medical applications comprises: a cell-incorporated substance that can be incorporated into a target cell specifically; and an acting substance that can act on the function of the target cell and is bound to the cell-incorporated substance.
- Who is the assignee on this patent?
- Suzuki Minako, Nakahara Taka, Ishikawa Hiroshi, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/54. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).